Central sensitization theory of migraine: Clinical implications

Headache

Volumn 46, Issue SUPPL. 4, 2006, Pages

  Dodick, David ^a   Silberstein, Stephen ^b  

^a MAYO CLINIC   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Central sensitization; Cutaneous allodynia; Dihydroergotamine; Migraine headache; Pathophysiology of migraine; Peripheral sensitization

Indexed keywords

ANTIEMETIC AGENT; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DIHYDROERGOTAMINE; INDOMETACIN; KETOROLAC; SUMATRIPTAN; TRIPTAN DERIVATIVE;

ALLODYNIA; BRAIN STEM; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTACT SENSITIZATION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; MIGRAINE; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; REVIEW; SENSITIZATION; SENSORY NERVE CELL; SENSORY STIMULATION; SKIN STIMULATION; THEORY; TREATMENT RESPONSE; TRIGEMINAL NUCLEUS;

ANALGESICS, NON-NARCOTIC; ANIMALS; CYCLOOXYGENASE INHIBITORS; DIHYDROERGOTAMINE; HUMANS; MIGRAINE DISORDERS; NOCICEPTORS; TRIGEMINAL CAUDAL NUCLEUS;

EID: 33750469654     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2006.00602.x     Document Type: Review

References (37)

1. Silberstein SD. Migraine pathophysiology and its clinical implications. Cephalalgia. 2004;24(suppl 2):2-7.
2. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack: Clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain. 2000;123(Pt 8):1703-1709.
3. Lidbeck J. Central hyperexcitability in chronic musculoskeletal pain: A conceptual breakthrough with multiple clinical implications. Pain Res Manag. 2002;7:81-92.
4. Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: Irritable nociceptors and deafferentation. Neurobiol Dis. 1998;5:209-227.
5. Zimmermann M. Pathophysiological mechanisms of fibromyalgia. Clin J Pain. 1991;7(suppl 1):S8-S15.
6. Marchettini P, Lacerenza M, Ieracitano D, Canal N. Sensitized nociceptors in reflex sympathetic dystrophies. Funct Neurol. 1989;4:135-140.
7. Merrill RL. Orofacial pain mechanisms and their clinical application. Dent Clin North Am. 1997;41:167-188.
8. Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature. 1996;384:560-564.
9. Strassman AM, Levy D. Response properties of dural nociceptors in relation to headache. J Neurophysiol. 2006;95:1298-1306.
10. Magerl W, Wilk SH, Treede RD. Secondary hyperalgesia and perceptual wind-up following intradermal injection of capsaicin in humans. Pain. 1998;74:257-268.
11. Costigan M, Woolf C. Pain: Molecular mechanisms. J Pain. 2000;1(suppl 1):35-44.
12. Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain. 1994;117(pt 1):199-210.
13. Yarnitsky D, Goor-Aryeh I, Bajwa ZH, et al. 2003 Wolff Award: Possible parasympathetic contributions to peripheral and central sensitization during migraine. Headache. 2003;43:704-714.
14. Piao ZG, Cho IH, Park CK, et al. Activation of glia and microglial p38 MAPK in medullary dorsal horn contributes to tactile hypersensitivity following trigeminal sensory nerve injury. Pain. 2006;121:219-231.
15. Moskowitz MA, Henrikson BM, Markowitz S, et al. Intra- and extracraniovascular nociceptive mechanisms and the pathogenesis of pain. In: Olesen J, Edvinsson L, eds. Basic Mechanisms of Headache. Amsterdam: Elsevier; 1988:429-437.
16. Burstein R, Yamamura H, Malick A, Strassman AM. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol. 1998;79:964-982.
17. Anthony M, Rasmussen BK. Migraine without aura. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches. New York: Raven Press; 1993:255-261.
18. Simone DA, Sorkin LS, Oh U, et al. Neurogenic hyperalgesia: Central neural correlates in responses of spinothalamic tract neurons. J Neurophysiol. 1991;66:228-246.
19. Torebjork HE, Lundberg LE, LaMotte RH. Central changes in processing of mechanoreceptive input in capsaicin-induced secondary hyperalgesia in humans. J Physiol. 1992;448:765-780.
20. McMahon SB, Lewin GR, Wall PD. Central hyperexcitability triggered by noxious inputs. Curr Opin Neurobiol. 1993;3:602-610.
21. Ren K, Dubner R. NMDA receptor antagonists attenuate mechanical hyperalgesia in rats with unilateral inflammation of the hindpaw. Neurosci Lett. 1993;163:22-26.
22. Woolf CJ, Shortland P, Reynolds M, Ridings J, Doubell T, Coggeshall RE. Reorganization of central terminals of myelinated primary afferents in the rat dorsal horn following peripheral axotomy. J Comp Neurol. 1995;360:121-134.
23. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol. 2000;47:614-624.
24. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain:Arace against the development of central sensitization. Ann Neurol. 2004;55:27-36.
25. Potrebic S, Ahn AH, Skinner K, Fields HL, Basbaum AI. Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin 1D receptors: Implications for the selective antimigraine action of triptans. J Neurosci. 2003;23:10988-10997.
26. Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci U S A. 2004;101:4274-4279.
27. Burstein R, Levy D, Jakubowski M. Effects of sensitization of trigeminovascular neurons to triptan therapy during migraine. Rev Neurol (Paris). 2005;161:658-660.
28. Hoskin KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. Brain. 1996;119(Pt 1):249-256.
29. Pozo-Rosich P, Oshinsky M. Effects of dihydroergotamine (DHE) on central sensitization of neruons in the trigeminal nucleus caudalis [abstract S19.003]. Presented at American Academy of Neurology 57th Annual Meeting; Miami Beach, Florida; April 9-16, 2005.
30. Gallagher RM. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group. Arch Neurol. 1996;53:1285-1291.
31. Rapoport AM, Bigal ME, Tepper SJ, Sheftell FD. Intranasal medications for the treatment of migraine and cluster headache. CNS Drugs. 2004;18:671-685.
32. Boureau F, Kappos L, Schoenen J, Esperanca P, Ashford E. A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine. Int J Clin Pract. 2000;54:281-286.
33. Ghilardi JR, Svensson CI, Rogers SD, Yaksh TL, Mantyh PW. Constitutive spinal cyclooxygenase-2 participates in the initiation of tissue injury-induced hyperalgesia. J Neurosci. 2004;24:2727-2732.
34. Seybold VS, Jia YP, Abrahams LG. Cyclooxygenase-2 contributes to central sensitization in rats with peripheral inflammation. Pain. 2003;105:47-55.
35. Jakubowski M, Levy D, Goor-Aryeh I, Collins B, Bajwa Z, Burstein R. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache. 2005;45:850-861.
36. Wang Y, Aun R, Tse FL. Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat. Biopharm Drug Dispos. 1998;19:571-575.
37. Humbert H, Cabiac MD, Dubray C, Lavene D. Human pharmacokinetics of dihydroergotamine administered by nasal spray. Clin Pharmacol Ther. 1996;60:265-275.